Th2-dependent cytokine release in patients treated with coronary angioplasty

Coronary Artery Disease

Volumn 19, Issue 3, 2008, Pages 133-137

  Brunetti, Natale Daniele ^b   Pepe, Martino ^a   Munno, Irene ^a   Tiecco, Fabio ^c   Quagliara, Donato ^a   De Gennaro, Luisa ^b   Gaglione, Antonio ^c   Di Biase, Matteo ^b   Favale, Stefano ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c Cardiology Department   (Italy)

Author keywords

Coronary angioplasty; Coronary atherosclerosis; Th2 dependent cytokine release

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; TH2 CELL; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; MALE; MIDDLE AGED; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 42349086750     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3282f3fbcb     Document Type: Article

References (54)

1. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169:203-214.
2. Zhang X, Niessner A, Nakajima T, Ma-Krupa W, Kopecky SL, Frye RL, et al. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res 2006; 98:524-531. Epub 2006 Jan 19.
3. Moyer CF, Sajuthi D, Tulli H, Williams JK. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol 1991; 138:951-960.
4. Fiotti N, Giansante C, Ponte E, Delbello C, Calabrese S, Zacchi T, et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999; 145:51-60.
5. Wang X, Feuerstein GZ, Gu JL, Lysko PG, Yue TL. Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis 1995; 115:89-98.
6. Gawaz M, Brand K, Dickfeld T, Pogatsa-Murray G, Page S, Bogner C, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148:75-85.
7. Amar J, Fauvel J, Drouet L, Ruidavets JB, Perret B, Chamontin B, et al. Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens 2006; 24:1083-1088.
8. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 1996; 97:769-776.
9. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127:263-271.
10. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of IL-6 in unstable angina. Circulation 1996; 94:874-887.
11. Biasucci LM, Liuzzo G, Fantuzzi A, Caligiuri G, Rebuzzi AG, Ginetti F, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first two days of hospitalization in unstable angina are associated with increased risk of inhospital coronary events. Circulation 1999; 99:2079-2084.
12. Simon AD, Yazdani S, Wang W, Schwartz A, Rabbani LE. Circulating levels of IL-1beta, a prothrombotic cytokine, are elevated in unstable angina vs. stable angina. J Thromb Thrombolysis 2000; 9:217-222.
13. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003; 91:133-136.
14. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsoufis C, Marinou K, et al. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction. Int J Cardiol 2007; 115:203-207. Epub 2006 Jun 19.
15. Yazdani S, Simon AD, Vidhun R, Gulotta C, Schwartz A, Rabbani LE. Inflammatory profile in unstable angina vs. stable angina in patients undergoing percutaneous interventions. Am Heart J 1998; 136:357-361.
16. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 b in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 1996; 16:1000-1006.
17. Lee YW, Kuhn H, Hennig B, Neish AS, Toborek M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol 2001; 33:83-94.
18. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 2005; 66:583-593.
19. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104:746-749.
20. Waehre T, Halvorsen B, Damas JK, Yndestad A, Brosstad F, Gullestad L, et al. Inflammatory imbalance between IL-10 and TNF-α in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 2002; 32:803-810.
21. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM; CAPTURE Study Investigators. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107:2109-2114. Epub 2003 Mar 31.
22. Szodoray P, Timar O, Veres K, Der H, Szomjak E, Lakos G, et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines - immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 2006; 64:336-344.
23. Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circ Res 2002; 90:1039-1040.
24. Foster PS, Martinez-Moczygemba M, Huston DP, Corry DB. Interleukins-4, - 5, and -13: emerging therapeutic targets in allergic disease. Pharmacol Ther 2002; 94:253-264.
25. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793.
26. Finkelman FD, Urban JF Jr. The other side of the coin: the protective role of the TH2 cytokines. J Allergy Clin Immunol 2001; 107:772-780.
27. de Vries JE. The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998; 102:165-169.
28. Corry DB. IL-13 in allergy: home at last. Curr Opin Immunol 1999; 11:610-614.
29. Te Velde AA, Huijbens RJ, Heije K, de Vries JE, Figdor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1β, tumor necrosis factor-α and IL-6 by human monocytes. Blood 1990; 76:1392.
30. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor κB (NF-κB) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270:9558-9563.
31. De Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, et al. Effects of IL-13 on phenotype, cytokine production, and cytokine function and cytotoxic function of human monocytes. J Immunol 1993; 151:6370-6381.
32. Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM-1. J Immunol 1992; 148:1086-1092.
33. Schnyder B, Lugli S, Feng N, Etter H, Lutz RA, Ryffel B, et al. Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. Blood 1996; 87:4286-4295.
34. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin J, Azzarone R. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998; 101:2129-2139.
35. Maggi E. The TH1/TH2 paradigm in allergy. Immunotechnology 1998; 3:233-244.
36. Mochizuki M, Bartels J, Mallet AI, Christophers E, Schroder JM. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol 1998; 160:60-68.
37. Zimmermann N, Hogan SP, Mishra A, Brandt EB, Bodette TR, Pope SM, et al. Murine eotaxin-2: a constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression. J Immunol 2000; 165:5839-5846.
38. Hoeck J, Woisetschlager M. STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts. J Immunol 2001; 166:4507-4515.
39. Ramadan MM, Kodama M, Mitsuma W, Ito M, Kashimura T, Ikrar T, et al. Impact of percutaneous coronary intervention on the levels of interleukin-6 and C-reactive protein in the coronary circulation of subjects with coronary artery disease. Am J Cardiol 2006; 98:915-917.
40. Brunetti ND, Munno I, Pellegrino PL, Ruggiero V, Correale M, Cuculo A, et al. Inflammatory cytokines imbalance after coronary angioplasty: links with coronary atherosclerosis. J Interv Cardiol 2007; 20:248-257. Published Online 26 June 2007.
41. de la Torre-Hernandez JM, Sainz-Laso F, Burgos V, Perez T, Figueroa A, Zueco J, Colman T. Comparison of C-reactive protein levels after coronary stenting with bare metal vs. sirolimus-eluting stents. Am J Cardiol 2005; 95:748-751.
42. Chalikias GK, Tziakas DN, Kaski JC, Hatzinikolaou EI, Stakos DA, Tentes IK, et al. Interleukin-18: Interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis 2005; 182:135-143.
43. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104:992-997.
44. Dominguez-Rodriguez A, Abreu-Gonzalez P, de la Rosa A, Vargas M, Ferrer J, Garcia M. Role of endogenous interleukin-10 production and lipid peroxidation in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty, interleukin-10 and primary angioplasty. Int J Cardiol 2005; 99:77-81.
45. Kozinski M, Krzewina-Kowalska A, Kubica J, Zbikowska-Gotz M, Dymek G, Piasecki R, et al. Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis - comparison with stable and unstable angina. Inflamm Res 2005; 54:187-193.
46. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100:793-798.
47. Vasse M, Paysant I, Soria J, Mirshahi SS, Vannier JP, Soria C. Downregulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol 1996; 93:955-961.
48. Soejima H, Miyamoto S, Kojima S, Hokamaki J, Tanaka T, Kawano H, et al. Coronary spastic angina in patients with connective tissue disease. Circ J 2004; 68:367-370.
49. Burns JC, Shimizu C, Shike H, Newburger JW, Sundel RP, Baker AL, et al. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun 2005; 6:438-444.
50. Walch L, Massade L, Dufilho M, Brunet A, Rendu F. Proatherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis 2006; 187:285-291. Epub 2005 Oct 24.
51. Lee YW, Kuhn H, Hennig B, Toborek M. IL-4 induces apoptosis of endothelial cells through the caspase-3-dependent pathway. FEBS Lett 2000; 485:122-126.
52. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104:163-167.
53. Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the Clear Platelets 1b study. J Am Coll Cardiol 2006; 48:2186-2191.
54. Arora M, Chen L, Paglia M, Gallagher I, Allen JE, Vyas YM, et al. Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc Natl Acad Sci U S A 2006; 103:7777-7782.